Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Aug;49(4):781-783.
doi: 10.1007/s15010-020-01556-8. Epub 2021 Jan 2.

Differential serological and neutralizing antibody dynamics after an infection by a single SARS-CoV-2 strain

Emmanuelle Billon-Denis  1   2 , Audrey Ferrier-Rembert  1 , Annabelle Garnier  1 , Laurence Cheutin  1 , Clarisse Vigne  1 , Emilie Tessier  1 , Jessica Denis  1 , Cyril Badaut  1 , Clémence Rougeaux  1 , Anne Depeille Wuille  1 , Hawa Timera  1 , Laet Itia Boutin  1 , Isabelle Drouet  1 , Noémie Verguet  1 , Flora Nolent  1 , Olivier Gorgé  1 , Olivier Ferraris  1 , Jean-Nicolas Tournier  3   4   5
Affiliations
Case Reports

Differential serological and neutralizing antibody dynamics after an infection by a single SARS-CoV-2 strain

Emmanuelle Billon-Denis et al. Infection. 2021 Aug.

Abstract

Background: We report here the case of two coworkers infected by the same SARS-CoV-2 strain, presenting two different immunological outcomes.

Case: One patient presented a strong IgG anti-receptor-binding domain immune response correlated with a low and rapidly decreasing titer of neutralizing antibodies. The other patient had a similar strong IgG anti-receptor-binding domain immune response but high neutralizing antibody titers.

Discussion and conclusion: Thus, host individual factors may be the main drivers of the immune response varying with age and clinical severity.

Keywords: COVID-19; IgG; Neutralizing antibody; Receptor-binding domain; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

None of the authors has any conflict of interest relevant to the content of this work. There are no competing interests.

Figures

Fig. 1
Fig. 1
Patients 1 and 2 IgG ELISA OD ratio against SARS-CoV-2 and seroneutralizing titers. a Green triangle, OD ratio RBD signal patient 1 (RBD P1); blue triangle, OD ratio RBD signal patient 2 (RBD P2). b Green sphere, seroneutralizing titers patient 1 (SN P1); blue sphere, seroneutralizing titers patient 2 (SN P2)
See this image and copyright information in PMC

References

    1. Morens DM, Daszak P, Markel H, Taubenberger JK. Pandemic COVID-19 joins history's pandemic legion. mBio. 2020;11:3. - PMC - PubMed
    1. Vabret N, Britton GJ, Gruber C, et al. Immunology of COVID-19: current state of the science. Immunity. 2020;52:910–941. doi: 10.1016/j.immuni.2020.05.002. - DOI - PMC - PubMed
    1. Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26:845–848. doi: 10.1038/s41591-020-0897-1. - DOI - PubMed
    1. To KKW, Tsang OTY, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20:565–574. doi: 10.1016/S1473-3099(20)30196-1. - DOI - PMC - PubMed
    1. Jiang S, Hillyer C, Du L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol. 2020;41:355–359. doi: 10.1016/j.it.2020.03.007. - DOI - PMC - PubMed

Publication types